The prevalence of metabolic syndrome in cardiovascular patients in Iran: a systematic review and meta-analysis.
Iran
Metabolic syndrome
cardiovascular
meta-analysis
prevalence
Journal
Diabetology & metabolic syndrome
ISSN: 1758-5996
Titre abrégé: Diabetol Metab Syndr
Pays: England
ID NLM: 101488958
Informations de publication
Date de publication:
03 Nov 2020
03 Nov 2020
Historique:
received:
24
06
2020
accepted:
26
10
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
10
12
2020
Statut:
epublish
Résumé
Cardiovascular disease is the cause of more than 50% of mortalities globally, and this rate has grown by 8.6% since the 60 s. One of the risk factors associated with cardiovascular disease and its resulting mortality rate is the metabolic syndrome. Different studies have reported inconsistent rates for the metabolic syndrome. However, no comprehensive study has been conducted to combine the results of existing studies. Thus, the present study was performed with the aim of determining the prevalence of metabolic syndrome among cardiovascular patients in Iran through a systematic review and meta-analysis. In this review study, the Scientific Information Database, Google Scholar, Science Direct, Scopus, PubMed, and Web of Science (ISI), databases were searched from January 2005 and until May 2020, to identify and extract related articles. To conduct the analysis, a random effects model was used, and the heterogeneity of the studies was examined using the I The prevalence of metabolic syndrome in cardiovascular patients in Iran in the 27 papers examined with a sample size of 44,735 patients was 34.2% (95% CI: 26.8-42.6%). A sensitivity analysis was performed to ensure the stability of the results, these results show that by omitting the prevalence from each study, the overall prevalence (34.2%) does not change significantly. the highest prevalence of metabolic syndrome in studies conducted in the period between 2015 and 2020, and this was reported as 55.3 (95% CI: 47.9-62.3) and the highest prevalence of metabolic syndrome in studies conducted in the methods of diagnosis IDF, and the rate was reported as 48 (95% CI: 36.5-59.8). based on meta-regression as the year of research increased, the prevalence of metabolic syndrome in cardiovascular patients in Iran also increased. However, with the increase in sample size, this prevalence decreased (p < 0.05). The results of this study indicate that metabolic syndrome is high in cardiovascular patients in Iran. Accordingly, by understanding its etiology and supervision at all levels, suitable solutions could be offered by providing feedback to hospitals.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiovascular disease is the cause of more than 50% of mortalities globally, and this rate has grown by 8.6% since the 60 s. One of the risk factors associated with cardiovascular disease and its resulting mortality rate is the metabolic syndrome. Different studies have reported inconsistent rates for the metabolic syndrome. However, no comprehensive study has been conducted to combine the results of existing studies. Thus, the present study was performed with the aim of determining the prevalence of metabolic syndrome among cardiovascular patients in Iran through a systematic review and meta-analysis.
METHOD
METHODS
In this review study, the Scientific Information Database, Google Scholar, Science Direct, Scopus, PubMed, and Web of Science (ISI), databases were searched from January 2005 and until May 2020, to identify and extract related articles. To conduct the analysis, a random effects model was used, and the heterogeneity of the studies was examined using the I
RESULTS
RESULTS
The prevalence of metabolic syndrome in cardiovascular patients in Iran in the 27 papers examined with a sample size of 44,735 patients was 34.2% (95% CI: 26.8-42.6%). A sensitivity analysis was performed to ensure the stability of the results, these results show that by omitting the prevalence from each study, the overall prevalence (34.2%) does not change significantly. the highest prevalence of metabolic syndrome in studies conducted in the period between 2015 and 2020, and this was reported as 55.3 (95% CI: 47.9-62.3) and the highest prevalence of metabolic syndrome in studies conducted in the methods of diagnosis IDF, and the rate was reported as 48 (95% CI: 36.5-59.8). based on meta-regression as the year of research increased, the prevalence of metabolic syndrome in cardiovascular patients in Iran also increased. However, with the increase in sample size, this prevalence decreased (p < 0.05).
CONCLUSIONS
CONCLUSIONS
The results of this study indicate that metabolic syndrome is high in cardiovascular patients in Iran. Accordingly, by understanding its etiology and supervision at all levels, suitable solutions could be offered by providing feedback to hospitals.
Identifiants
pubmed: 33292427
doi: 10.1186/s13098-020-00605-4
pii: 10.1186/s13098-020-00605-4
pmc: PMC7607701
doi:
Types de publication
Journal Article
Langues
eng
Pagination
96Subventions
Organisme : Deputy for Research and Technology, Kermanshah University of Medical Sciences
ID : 30090000
Références
Arch Gerontol Geriatr. 2006 Jan-Feb;42(1):35-45
pubmed: 16046242
Am Heart J. 2006 Oct;152(4):785-92
pubmed: 16996859
ScientificWorldJournal. 2009 Feb 14;9:86-96
pubmed: 19219372
Diabetes Care. 2005 Jul;28(7):1769-78
pubmed: 15983333
Circulation. 2003 Jan 28;107(3):391-7
pubmed: 12551861
Int J Vitam Nutr Res. 2005 Jul;75(4):297-304
pubmed: 16229347
Diabetes Res Clin Pract. 2007 Jun;76(3):449-54
pubmed: 17141913
Diabetes Res Clin Pract. 2007 Aug;77(2):251-7
pubmed: 17234299
Diabetol Metab Syndr. 2019 Aug 27;11:73
pubmed: 31467595
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
Sci Total Environ. 2019 Feb 20;652:1318-1330
pubmed: 30586817
JAMA. 2002 Jan 16;287(3):356-9
pubmed: 11790215
Exp Clin Endocrinol Diabetes. 2008 Oct;116(9):525-31
pubmed: 18523915
Coron Artery Dis. 2007 May;18(3):163-8
pubmed: 17429288
Ann Acad Med Singap. 2009 Feb;38(2):142-9
pubmed: 19271043
Rev Panam Salud Publica. 2012 Aug;32(2):131-9
pubmed: 23099874
Diabetes Care. 2006 Apr;29(4):901-7
pubmed: 16567835
Diabetes Care. 2001 Apr;24(4):683-9
pubmed: 11315831
Circulation. 2000 Jul 4;102(1):42-7
pubmed: 10880413
Int J Stroke. 2017 Jan;12(1):13-32
pubmed: 27794138
Arch Med Res. 2009 Jul;40(5):399-405
pubmed: 19766905
J Am Coll Cardiol. 2006 Apr 18;47(8):1588-94
pubmed: 16630995
Indian J Dermatol Venereol Leprol. 2016 Sep-Oct;82(5):510-8
pubmed: 27297282
Diabetes Care. 2005 Feb;28(2):385-90
pubmed: 15677797
Clin Dermatol. 2018 Jan - Feb;36(1):9-13
pubmed: 29241759
JAMA. 2015 May 19;313(19):1973-4
pubmed: 25988468
Ann Acad Med Singap. 2005 Apr;34(3):243-9
pubmed: 15902345
Cardiol Res. 2016 Dec;7(6):202-208
pubmed: 28197293
Circulation. 2004 Jan 27;109(3):433-8
pubmed: 14744958
J Health Popul Nutr. 2017 Nov 13;36(1):36
pubmed: 29132438
Rev Port Cardiol. 2019 May;38(5):325-332
pubmed: 31221487
JAMA. 2002 Dec 4;288(21):2709-16
pubmed: 12460094
Ann Nutr Metab. 2005 Jan-Feb;49(1):3-8
pubmed: 15735362
Nutr Metab Cardiovasc Dis. 2009 Jul;19(6):401-8
pubmed: 19091534
Korean Circ J. 2016 Mar;46(2):229-38
pubmed: 27014354
Res Cardiovasc Med. 2014 Aug;3(3):e20270
pubmed: 25478548
Diabetes Care. 2005 Apr;28(4):882-7
pubmed: 15793190
Int J Prev Med. 2013 Jan;4(1):110-4
pubmed: 23411742
Med Clin North Am. 2006 Jul;90(4):573-91
pubmed: 16843763
Rev Endocr Metab Disord. 2019 Mar;20(1):79-88
pubmed: 30887405
Obes Rev. 2005 Aug;6(3):191-2
pubmed: 16045632
Res Cardiovasc Med. 2016 Jan 06;5(1):e30619
pubmed: 26889461
Acta Biomed. 2015 Sep 14;86(2):157-61
pubmed: 26422430
Diabetes Care. 2003 Mar;26(3):861-7
pubmed: 12610050
Circulation. 2003 Jul 29;108(4):414-9
pubmed: 12860911
Nutrients. 2019 Jun 29;11(7):
pubmed: 31261967
Diabetes. 2003 May;52(5):1210-4
pubmed: 12716754
J Am Geriatr Soc. 2006 Sep;54(9):1317-24
pubmed: 16970637
Environ Sci Pollut Res Int. 2019 Nov;26(31):32645-32665
pubmed: 31576506
Diabetes Care. 2003 Apr;26(4):1251-7
pubmed: 12663606